Do analysts prefer GRDX or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRDX or CURX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Curanex Pharmaceuticals N/A -85.41% -82.11%

Do analysts recommend CURX or SKYE?

Skye Bioscience has a consensus price target of $8.50, suggesting a potential upside of 1,355.48%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, CURX or SKYE?

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is CURX or SKYE more profitable?

Curanex Pharmaceuticals' return on equity of -85.41% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% Skye Bioscience N/A -217.27% -162.39%

Do analysts rate NEUP or CURX?

Neuphoria Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 435.71%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Neuphoria Therapeutics is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NEUP or CURX more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Curanex Pharmaceuticals N/A -85.41% -82.11%

Do analysts prefer LGVN or CURX?

Longeveron currently has a consensus target price of $5.50, indicating a potential upside of 609.68%. Given Longeveron's stronger consensus rating and higher possible upside, equities analysts clearly believe Longeveron is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate KZIA or CURX?

Novogen presently has a consensus target price of $25.80, indicating a potential upside of 106.48%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts plainly believe Novogen is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, KZIA or CURX?

Curanex Pharmaceuticals has lower revenue, but higher earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 687.23 -$13.41M N/A N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A

Is KZIA or CURX more profitable?

Novogen's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Curanex Pharmaceuticals N/A -85.41% -82.11%

Curanex Pharmaceuticals (CURX) Competitors

$0.21 0.00 (-0.05%)

As of 01:48 PM Eastern

Compare

CURX vs. GRDX, SKYE, NEUP, LGVN, and KZIA

Should you buy Curanex Pharmaceuticals stock or one of its competitors? MarketBeat compares Curanex Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Curanex Pharmaceuticals include Entero Therapeutics (GRDX), Skye Bioscience (SKYE), Neuphoria Therapeutics (NEUP), Longeveron (LGVN), and Novogen (KZIA).

How does Curanex Pharmaceuticals compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Curanex Pharmaceuticals (NASDAQ:CURX) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Entero Therapeutics' return on equity of -49.81% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Curanex Pharmaceuticals	Neutral

Curanex Pharmaceuticals has lower revenue, but higher earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	493.89	-$6.39M	-$1.88	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Summary

Curanex Pharmaceuticals beats Entero Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Skye Bioscience?

Curanex Pharmaceuticals (NASDAQ:CURX) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

In the previous week, Skye Bioscience had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 0.00 equaled Skye Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
Skye Bioscience	Neutral

Curanex Pharmaceuticals' return on equity of -85.41% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
Skye Bioscience	N/A	-217.27%	-162.39%

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Skye Bioscience has a consensus price target of $8.50, suggesting a potential upside of 1,355.48%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

21.1% of Skye Bioscience shares are held by institutional investors. 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Skye Bioscience beats Curanex Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for Neuphoria Therapeutics and 0 mentions for Curanex Pharmaceuticals. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Curanex Pharmaceuticals	Neutral

Neuphoria Therapeutics' return on equity of -76.93% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Neuphoria Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 435.71%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Neuphoria Therapeutics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neuphoria Therapeutics has higher revenue and earnings than Curanex Pharmaceuticals. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.35	-$370K	-$11.06	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Summary

Neuphoria Therapeutics beats Curanex Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Longeveron?

Longeveron (NASDAQ:LGVN) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Longeveron currently has a consensus target price of $5.50, indicating a potential upside of 609.68%. Given Longeveron's stronger consensus rating and higher possible upside, equities analysts clearly believe Longeveron is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.0% of Longeveron shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Longeveron had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for Longeveron and 0 mentions for Curanex Pharmaceuticals. Longeveron's average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Longeveron	Neutral
Curanex Pharmaceuticals	Neutral

Curanex Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Curanex Pharmaceuticals' return on equity of -85.41% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,844.49%	-202.41%	-140.67%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Curanex Pharmaceuticals has lower revenue, but higher earnings than Longeveron. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	20.12	-$22.70M	-$1.13	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Summary

Longeveron beats Curanex Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Novogen?

Novogen (NASDAQ:KZIA) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Curanex Pharmaceuticals has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	687.23	-$13.41M	N/A	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

In the previous week, Novogen's average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Novogen	Neutral
Curanex Pharmaceuticals	Neutral

Novogen presently has a consensus target price of $25.80, indicating a potential upside of 106.48%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts plainly believe Novogen is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.9% of Novogen shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Novogen's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Summary

Novogen beats Curanex Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CURX vs. The Competition

Export

Metric	Curanex Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.98M	$11.50B	$6.82B	$12.97B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-0.78	791.56	279.98	25.51
Price / Sales	N/A	943.82	649.15	115.49
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	0.53	10.41	11.14	6.35
Net Income	-$4.22M	$2.80B	$3.48B	$347.60M
7 Day Performance	7.07%	1.82%	2.39%	3.04%
1 Month Performance	-16.83%	-2.95%	-2.87%	-2.15%
1 Year Performance	N/A	155.26%	64.14%	21.14%

Curanex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CURX Curanex Pharmaceuticals	0.8399 of 5 stars	$0.21 0.0%	N/A	N/A	$5.98M	N/A	N/A	N/A	Positive News
GRDX Entero Therapeutics	N/A	$3.09 +18.7%	N/A	N/A	$21.32M	$40K	N/A	9	Positive News Gap Down
SKYE Skye Bioscience	1.6734 of 5 stars	$0.60 -1.8%	$8.50 +1,307.3%	-82.9%	$21.23M	N/A	N/A	11	News Coverage
NEUP Neuphoria Therapeutics	2.2472 of 5 stars	$3.84 +1.1%	$21.00 +446.9%	-51.2%	$20.74M	$15.65M	N/A	N/A
LGVN Longeveron	1.7067 of 5 stars	$0.67 +12.3%	$5.50 +723.4%	-55.2%	$20.72M	$1.20M	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CURX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. GRDX, SKYE, NEUP, LGVN, and KZIA

How does Curanex Pharmaceuticals compare to Entero Therapeutics?

Summary

How does Curanex Pharmaceuticals compare to Skye Bioscience?

Summary

How does Curanex Pharmaceuticals compare to Neuphoria Therapeutics?

Summary

How does Curanex Pharmaceuticals compare to Longeveron?

Summary

How does Curanex Pharmaceuticals compare to Novogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. GRDX, SKYE, NEUP, LGVN, and KZIA

How does Curanex Pharmaceuticals compare to Entero Therapeutics?

Do analysts prefer GRDX or CURX?

Do insiders and institutionals believe in GRDX or CURX?

Is GRDX or CURX more profitable?

Does the media prefer GRDX or CURX?

Which has stronger earnings & valuation, GRDX or CURX?

Summary

How does Curanex Pharmaceuticals compare to Skye Bioscience?

Does the media refer more to CURX or SKYE?

Is CURX or SKYE more profitable?

Which has higher valuation & earnings, CURX or SKYE?

Do analysts recommend CURX or SKYE?

Do insiders and institutionals have more ownership in CURX or SKYE?

Summary

How does Curanex Pharmaceuticals compare to Neuphoria Therapeutics?

Does the media refer more to NEUP or CURX?

Is NEUP or CURX more profitable?

Do analysts rate NEUP or CURX?

Do institutionals and insiders hold more shares of NEUP or CURX?

Which has better valuation & earnings, NEUP or CURX?

Summary

How does Curanex Pharmaceuticals compare to Longeveron?

Do analysts prefer LGVN or CURX?

Do institutionals & insiders have more ownership in LGVN or CURX?

Does the media prefer LGVN or CURX?

Is LGVN or CURX more profitable?

Which has preferable valuation and earnings, LGVN or CURX?

Summary

How does Curanex Pharmaceuticals compare to Novogen?

Which has stronger earnings and valuation, KZIA or CURX?

Does the media refer more to KZIA or CURX?

Do analysts rate KZIA or CURX?

Do institutionals and insiders have more ownership in KZIA or CURX?

Is KZIA or CURX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools